Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Chalks Up Record Profits as US Unit Buoys Sales
May 10, 2013
- DSP Sales Down 0.8% Due to Long-Listed Product Sales Decline, Double-Digit Growth in Profits
May 10, 2013
- Takeda Sees Sales Rise on Expanding Europe, Emerging Market Biz in FY2012, Yet Operating Profit Sags 50%
May 10, 2013
- No Prospects of Reaching Agreement on Delivery Prices with Wholesalers Even after the Fiscal Year End: Pres. Tajiri of Medical System Network
May 10, 2013
- Eisai to Launch the Obesity Treatment Belviq in the US in June
May 10, 2013
- Ono, DSP to Expand Business for Limaprost in China
May 10, 2013
- Santen’s FY2012 Operating Profit Sinks 7% as Eylea Launch Drives Up Cost Ratio
May 9, 2013
- Astellas Partners with Drais Pharmaceuticals to Develop Nocturia Treatment
May 9, 2013
- MTPC Annual Sales Up 3% with Gilenya Royalities, Remicade Growth
May 9, 2013
- Baxter’s Cell Culture-Based Prototype Flu Vaccine Obtains Approval
May 9, 2013
- Takeda to Acquire US Dengue Vaccine Developer Inviragen
May 9, 2013
- Kowa to Initiate Domestic PI Clinical Study of Anticancer Drug Codeveloped by NanoCarrier
May 9, 2013
- IFRS Implications to Be Seen in In-Licensed Products, M&A Processing
May 9, 2013
- Maruishi Licenses New Kappa Opioid Agonist from Cara Therapeutics
May 8, 2013
- BMKK to Increase Number of MRs to 1,000 by 2015
May 8, 2013
- Astellas: FDA Advisory Panel Did Not Back Approval of Tivozanib
May 8, 2013
- Shionogi Sponsors EMPATHY Study to Build New Evidence for Statins
May 8, 2013
- AnGes MG Eyes PIII Trial for Collategene in US, Europe by 2013-End
May 8, 2013
- Nichi-Iko Voluntarily Recalls Enalapril Maleate Tablets
May 7, 2013
- BI Japan’s Ethical Drug Sales Up 7.3% with Prazaxa Sales of 23.5 Billion Yen
May 7, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…